Evaluate Forecasting Excellence: The Value of Outliers in Consensus Forecasting

Thumbnail
Thumbnail
Thumbnail

Key Report Themes

  • Upside/downside radio metrics that identify companies that could either outperform in the coming years or are at risk
  • Companies that could follow a different trajectory compared to the scenario outlined by consensus forecasts
  • More details on the value of a company’s pipeline for which forecasts are not yet available

A perspective on the portfolio strategy of the top 20 pharma companies.

Evaluate Forecasting Excellence: The Value of Outliers in Consensus Forecasting analyses the portfolio strategy of the top 20 pharmaceutical companies by leveraging the maximum and minimum forecast within EvaluatePharma® consensus. 

Download Report

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.